---
title: "Braveheart Bio appoints Marc Evanchik as CSO and Brittany de Temple as SVP, advancing towards global Phase 3 trials."
description: "The company has promoted Marc Evanchik to the position of Chief Scientific Officer to oversee clinical development, research, and scientific strategy. Concurrently, Brittany de Temple has joined as th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274980565.md"
published_at: "2026-02-05T13:03:44.000Z"
---

# Braveheart Bio appoints Marc Evanchik as CSO and Brittany de Temple as SVP, advancing towards global Phase 3 trials.

> The company has promoted Marc Evanchik to the position of Chief Scientific Officer to oversee clinical development, research, and scientific strategy. Concurrently, Brittany de Temple has joined as the Senior Vice President of Development Operations to enhance preparedness for expanded clinical operations. These key appointments come amidst the company's progress towards the upcoming launch of global initiatives.

The company has promoted Marc Evanchik to the position of Chief Scientific Officer to oversee clinical development, research, and scientific strategy. Concurrently, Brittany de Temple has joined as the Senior Vice President of Development Operations to enhance preparedness for expanded clinical operations. These key appointments come amidst the company's progress towards the upcoming launch of global initiatives.

### Related Stocks

- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [XHE.US - SPDR S&P Health Equip](https://longbridge.com/en/quote/XHE.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [MBIO.US - Mustang Bio](https://longbridge.com/en/quote/MBIO.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [HBIO.US - Harvard Bioscience](https://longbridge.com/en/quote/HBIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Tandem Diabetes Care 的盈利前景 | Tandem Diabetes Care（納斯達克代碼：TNDM）定於 2026 年 2 月 19 日公佈季度財報，分析師預測每股收益（EPS）為-0.07 美元。投資者對在之前每股收益超出預期後，能夠獲得積極的指引抱有希望，這一超預期導致 | [Link](https://longbridge.com/en/news/276258760.md) |
| Assetmark Inc. 出售了 18,236 股碩騰公司（Zoetis Inc.）的股票，股票代碼為$ZTS | Assetmark Inc. 在第三季度將其在 Zoetis Inc. (NYSE:ZTS) 的持股減少了 69.1%，出售了 18,236 股，剩餘 8,173 股，市值為 1,196,000 美元。其他機構投資者也調整了他們的持股。分析 | [Link](https://longbridge.com/en/news/276508320.md) |
| Zydus Lifesciences 獲得美國 FDA 批准其 32 毫克波生坦片 | Zydus Lifesciences 獲得美國 FDA 對 32 毫克博生坦片的批准 | [Link](https://longbridge.com/en/news/276229686.md) |
| 阿伯丁集團有限公司在 Tectonic Therapeutic, Inc. $TECX 中建立了價值 559 萬美元的頭寸 | 阿伯丁集團（Aberdeen Group plc）在 Tectonic Therapeutic, Inc.（納斯達克代碼：TECX）中獲得了約 559 萬美元的新頭寸，在第三季度購買了 356,176 股。這項投資約佔 Tectonic 股 | [Link](https://longbridge.com/en/news/276507461.md) |
| 瑞穗證券維持對 Pulse Biosciences（PLSE）的買入評級 | 瑞穗證券對 Pulse Biosciences（PLSE）維持買入評級，目標價為 30 美元。分析師 Anthony Petrone 以 7.3% 的平均回報率和 50.11% 的成功率而聞名，專注於醫療保健行業。此外，TipRanks 也 | [Link](https://longbridge.com/en/news/276443189.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.